The American journal of sports medicine · 2026
Dermal Allograft Augmentation for Open Gluteus Medius Repair: A Case Series at 2-Year Follow-up.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Quesada-Jimenez Roger, O'Brien Elizabeth J, Walsh Elizabeth G, Kahana-Rojkind Ady H, Kuhns Benjamin D, Domb Benjamin G
Аннотация
BACKGROUND: Gluteus medius (GM) tears are a common cause of peritrochanteric regional pain and disability among middle-aged and older populations. While largely successful, when primary repair fails, it is often attributed to poor tendon quality. Dermal allograft augmentation offers a solution for this patient population by enhancing the biological and mechanical properties of the repair construct.
PURPOSE: To evaluate the outcomes of open isolated GM repair with dermal allograft augmentation at 2-year follow-up, with a sex-based subanalysis comparing clinical outcomes in male versus female patients.
STUDY DESIGN: Case series; Level of evidence, 4.
METHODS: Prospectively collected data were retrospectively analyzed for all patients who underwent open GM repair with dermal allograft augmentation between June 2016 and April 2022. Included patients had complete preoperative and 2-year follow-up data for the following patient-reported outcome measures (PROMs): modified Harris Hip Score (mHHS), Non-Arthritic Hip Score (NAHS), International Hip Outcome Tool-12 (iHOT-12), visual analog scale for pain, and patient satisfaction; if complete 2-year follow-up data were not available, patients had a documented endpoint such as further surgery. Clinically relevant thresholds, complications, and secondary surgery were reported.
RESULTS: A total of 23 hips (18 female, 5 male) were included in this study. There were 17 primary procedures with dermal allograft augmentation (73.9%) and 6 revisions after prior GM repair without previous dermal allograft augmentation (26.1%). A significant improvement was observed on all evaluated PROMs, with 1 reoperation (4.4%) for a recurrent tear. A high percentage of patients achieved the minimal clinically important difference for the mHHS (86.4%), NAHS (81.8%), and iHOT-12 (72.7%). Moreover, 16 (72.7%) answered the patient acceptable symptom state anchor question positively. A sex-based subanalysis showed that female patients demonstrated a greater postoperative improvement on PROMs and a higher rate of achieving clinically relevant thresholds compared with male patients.
CONCLUSION: Patients with extensive degenerative GM tears who underwent repair with dermal allograft augmentation had favorable outcomes with significant improvements on PROMs and low reoperation rates at short-term follow-up.
PURPOSE: To evaluate the outcomes of open isolated GM repair with dermal allograft augmentation at 2-year follow-up, with a sex-based subanalysis comparing clinical outcomes in male versus female patients.
STUDY DESIGN: Case series; Level of evidence, 4.
METHODS: Prospectively collected data were retrospectively analyzed for all patients who underwent open GM repair with dermal allograft augmentation between June 2016 and April 2022. Included patients had complete preoperative and 2-year follow-up data for the following patient-reported outcome measures (PROMs): modified Harris Hip Score (mHHS), Non-Arthritic Hip Score (NAHS), International Hip Outcome Tool-12 (iHOT-12), visual analog scale for pain, and patient satisfaction; if complete 2-year follow-up data were not available, patients had a documented endpoint such as further surgery. Clinically relevant thresholds, complications, and secondary surgery were reported.
RESULTS: A total of 23 hips (18 female, 5 male) were included in this study. There were 17 primary procedures with dermal allograft augmentation (73.9%) and 6 revisions after prior GM repair without previous dermal allograft augmentation (26.1%). A significant improvement was observed on all evaluated PROMs, with 1 reoperation (4.4%) for a recurrent tear. A high percentage of patients achieved the minimal clinically important difference for the mHHS (86.4%), NAHS (81.8%), and iHOT-12 (72.7%). Moreover, 16 (72.7%) answered the patient acceptable symptom state anchor question positively. A sex-based subanalysis showed that female patients demonstrated a greater postoperative improvement on PROMs and a higher rate of achieving clinically relevant thresholds compared with male patients.
CONCLUSION: Patients with extensive degenerative GM tears who underwent repair with dermal allograft augmentation had favorable outcomes with significant improvements on PROMs and low reoperation rates at short-term follow-up.